News from arena pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 07, 2019, 16:01 ET Arena Reports Third Quarter Financial Results with Continued Progress on Clinical Programs

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, ...

Nov 06, 2019, 08:30 ET Arena Pharmaceuticals Presented New Data Highlighting the Human Mass Balance and Metabolism Profile of Etrasimod at AAPS

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data evaluating the human mass balance, metabolic disposition, and pharmacokinetics (PK) of...

Nov 05, 2019, 17:41 ET Arena Pharmaceuticals to Present at Upcoming Investor Conferences

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will present at the upcoming investor...

Oct 31, 2019, 08:30 ET Arena Pharmaceuticals to Release Third Quarter 2019 Financial Results and Provide Corporate Update on November 7

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2019 financial results and provide a corporate update on Thursday, November ...

Oct 28, 2019, 08:30 ET Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in the Phase 2 ADVISE trial evaluating etrasimod, an ...

Oct 22, 2019, 16:01 ET Arena Pharmaceuticals Presented New Data Analyses Demonstrating the Long-Term Safety and Efficacy of Once-Daily Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis at UEG Week

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate...

Oct 18, 2019, 03:01 ET Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new open-label extension data from the Phase 2 OASIS trial for its investigative drug...

Sep 26, 2019, 08:30 ET Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral,...

Sep 25, 2019, 08:30 ET Arena Pharmaceuticals to Present at the Cantor Global Healthcare Conference on October 2

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, President and Chief Executive Officer of Arena, will present a...

Sep 17, 2019, 08:30 ET Arena Pharmaceuticals to Present New Preclinical Atopic Dermatitis Data for Etrasimod at the European Society for Dermatologic Research Annual Meeting

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new preclinical data for etrasimod, an investigational, once-daily, oral, selective...

Sep 09, 2019, 08:30 ET Arena Pharmaceuticals Presented New Patient-Reported Outcomes Data for Olorinab at the European Society of Neurogastroenterology & Motility NeuroGASTRO 2019 Meeting

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting,...

Aug 28, 2019, 08:30 ET Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor...

Aug 07, 2019, 16:01 ET Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Initiation of Etrasimod ELEVATE UC 52 and Olorinab CAPTIVATE Trials

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30,...

Jul 31, 2019, 08:30 ET Arena Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on August 7

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2019 financial results and provide a corporate update on Wednesday, August ...

Jul 25, 2019, 08:30 ET Arena Pharmaceuticals Announces First Subject Dosed in CAPTIVATE Phase 2 Trial Evaluating Olorinab in Abdominal Pain Associated with Irritable Bowel Syndrome

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in the Phase 2 CAPTIVATE trial evaluating olorinab,...

Jun 17, 2019, 08:30 ET Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in ELEVATE UC 52, the first of two pivotal trials...

Jun 13, 2019, 08:30 ET Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference on June 19

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a...

May 17, 2019, 08:30 ET Arena Pharmaceuticals' Presence at Digestive Disease Week (DDW) Reinforces Commitment to the Gastrointestinal Disease Community

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has initiated sites for its ELEVATE UC Phase 3 global program to evaluate...

May 13, 2019, 08:30 ET Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor...

May 08, 2019, 16:01 ET Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2019 Financial Results

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31,...

May 01, 2019, 08:30 ET Arena Pharmaceuticals to Release First Quarter 2019 Financial Results and Provide Corporate Update on May 8

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2019 financial results and provide a corporate update on Wednesday, May 8,...

Apr 03, 2019, 08:30 ET Arena Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 10

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a...

Mar 08, 2019, 08:30 ET Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral,...

Feb 26, 2019, 16:01 ET Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full-year...

Feb 21, 2019, 08:30 ET Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a...